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ho Needs a Defibrillator?
he Beat Goes On*
ohn D. Fisher, MD, FACC
ronx, New York
n this issue of the Journal, Elhendy et al. (1) and Singh et
l. (2) wrestle with the problem of how to predict which
atients who qualify for implantation of an automatic
mplantable cardioverter-defibrillator (ICD) will actually
enefit from the device. These studies reflect a renewed
nterest in risk stratification to improve the specificity of the
election process, to improve the cost-effectiveness of ICD
herapy, and to reduce the number needed to treat (NNT)
o save one life.
See pages 1712 and 1721
Over the last decade, there has been a dramatic rise in the
umber of ICDs in use. This has been driven by a
ombination of results from a successive series of random-
zed clinical trials and by easier implantation techniques. In
ddition, a great expansion has occurred in the indications
or primary prevention (prophylactic) ICD use. At the same
ime, many restrictions have been discarded, including
ailure to respond to antiarrhythmic drugs, presence of
on-sustained ventricular tachycardia (VT), and (usually)
T inducibility at electrophysiologic studies (EPS). Thus,
ver larger numbers of patients at risk of an arrhythmic
vent can be offered the protection that is provided by an
CD. At the same time, however, the percentage of patients
ith an ICD who receive appropriate therapy has decreased,
or example, from 50% to 55% in Multicenter Automatic
efibrillator Implantation Trial I (MADIT I) (3) and
ulticenter Unsustained Tachycardia Trial (MUSTT) (4)
o about 25% in the Sudden Cardiac Death-Heart Failure
rial (SCD-HeFT) (5). This in turn increases the NNT to
ave one life calculated at any designated follow-up time,
nd therefore the cost per life saved.
Under these circumstances, insurers have parsed the data
o discourage implantation of “unnecessary” ICDs. Thus,
or a time (now rescinded) Medicare in the U.S. imposed a
equirement of a 120 ms minimum QRS duration on
atients who would otherwise qualify for an ICD under
ADIT II criteria (6). Following publication of the SCD-
eFT study, Medicare imposed another series of restric-
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Medicine, Division of Cardiology, Arrhythmia Service,
ontefiore Medical Center and the Albert Einstein College of Medicine, Bronx,t
ew York. Dr. Fisher is a consultant for Medtronic and investigator or speaker for St.
ude Medical and Guidant, all of which manufacture ICDs.ions (7,8), some of which were based on an attempt to
ollate the results of several trials so as to make the
uidelines more consistent. Other restrictions, such as a
equirement for a registry or participation in an approved
rotocol for any primary prevention implant, represent a
ew level of supervision and de facto restriction. At the
ame time, Medicare called for additional investigation into
creening tests or risk stratifiers that could help to assure
hat a higher percentage of patients receiving defibrillators
ould actually benefit from them (8). Physicians and trial
esigners should carefully ponder the desirability of this
hift of inclusion/exclusion criteria from trial designers to
nsurers. These concerns have already prompted a number
f commentaries (9,10).
Elhendy et al. (1) found that evidence of ischemia based
n a stress-echocardiographic test was an independent
redictor of death. Other independent predictors were
pontaneous or induced sustained VT at the time of the
riginal ICD placement. This was a consecutive series of
atients with a history of coronary artery disease (CAD) and
rior ICD implantation who had indications for a stress-
chocardiographic study an average of three years after the
CD implant. It was not a consecutive series of all patients
ith an ICD. Although the investigators do not describe
schemia testing prior to the initial implant, most protocols
nd guidelines call for initial correction of ischemia. The
arlier MADIT (3) and MUSTT (4) studies also used
nducibility of VT before the first ICD implant. In the
ADIT I study, inducibility was necessary to continue in
he study. With the MUSTT study, the non-inducible
registry) patients were followed prospectively along with
hose randomized to no anti-arrhythmic therapy, or to
nti-arrhythmic therapy including ICD placement. As with
lhendy et al. (1), in the larger MUSTT study of over 2,200
atients, inducibility of VT was statistically predictive of
ubsequent events (4,11). However, sensitivity and specific-
ty were low enough so that EPS currently has less effect on
he decision to implant.
The importance of ischemia can be inferred from previ-
us studies. One of the few ICD trials that failed to show
dvantage for the device was the Coronary Artery Bypass
raft-ICD Patch (CABG-Patch) trial (12). In this study,
ll patients received best possible surgical revascularization
nd were randomized to receive an ICD or not. The fully
evascularized patients had no added benefit from the ICD.
n the MUSTT trial, patients implanted within several days
ollowing surgical revascularization also had no benefit from
he ICD (13). Taken together with the Elhendy et al. (1)
eport, the implication is clear: patients with CAD have a
rogressive process and should be tested periodically for new
schemia; and such ischemia should be corrected if possible.
till, it remains uncertain whether continued absence of
vidence of ischemia or correction of newly identified
schemia would obviate the advantages of ICD implanta-
ion.
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Editorial Comment November 1, 2005:1727–8Singh et al. (2) found that a hospital admission for heart
ailure during follow up was a strong predictor of reaching
he end points of VT or ventricular fibrillation (VF), or the
ombined end point of VT, VF, or death. This is another
eminder of the dynamic and progressive nature of heart
isease in many patients. The findings are consistent with
arlier reports that ICD patients who receive their implant
or arrhythmia rather than heart failure indications tended
o have more events including mortality during follow up if
jection fractions were lower (14,15). In contrast, patients
mplanted primarily for heart failure indications (e.g., SCD-
eFT) benefited less from the ICD if they were in New
ork Heart Association functional class III versus class II
5). This again marks worsening heart failure as a good
redictor of a bad outcome. It has long been known that
imply receiving an ICD shock has been associated with a
oorer prognosis (16).
In summary, both papers by Elhendy et al. (1) and Singh
t al. (2) in this issue of the Journal remind us that patients
ave disease that progresses at an unpredictable rate, and
hat some patients are lucky enough to have warning signs
spontaneous or through testing) that can help avert a
ataclysmic event. For the physician the challenge is to learn
o recognize and use these warning signs, and to develop
etter predictive tests. For insurers and for society, the
hallenge is how to pay for it all (17–20). For citizens at
arge, the challenge is to reach a consensus on just how to
alance and to prioritize these competing forces. “All well
nd good, but not for my patient (or loved one)” is an
ttitude challenge we all must face.
eprint requests and correspondence: Dr. John D. Fisher,
ardiology/Arrhythmia Offices, North 2, Montefiore Medical
enter, 111 East 210th Street, Bronx, New York 10467. E-mail:
fisher@montefiore.org.
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